KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) EPS (Weighted Average and Diluted) (2018 - 2026)

Esperion Therapeutics filings provide 8 years of EPS (Weighted Average and Diluted) readings, the most recent being $0.32 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 390.91% to $0.32 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.11, a 56.0% increase, with the full-year FY2025 number at -$0.11, up 60.71% from a year prior.
  • EPS (Weighted Average and Diluted) hit $0.32 in Q4 2025 for Esperion Therapeutics, up from -$0.16 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.34 in Q1 2024 to a low of -$3.5 in Q1 2021.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.48 (2023), compared with a mean of -$0.77.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 390.91% in 2025, down 161.76% in 2025.
  • Esperion Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.53 in 2021, then skyrocketed by 51.63% to -$0.74 in 2022, then soared by 32.43% to -$0.5 in 2023, then surged by 78.0% to -$0.11 in 2024, then surged by 390.91% to $0.32 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $0.32 (Q4 2025), -$0.16 (Q3 2025), and -$0.06 (Q2 2025) per Business Quant data.